David A. Cooper - Concepedia

Author

David A. Cooper

Also Known As

Cooper, David, D A Cooper, D COOPER, D Cooper, D. A. COOPER, D. A. Cooper, D. Cooper, D.A. Cooper, DAVID A. COOPER, David A Cooper

180

Publications

11.1K

Citations

H-Index

102

Concepts

All Affiliations

UNSW Sydney National Centre for Clinical Research on Emerging Drugs HIV Netherlands Australia Thailand Research Collaboration Chulalongkorn University St Vincent's Hospital Sydney

About

David A. Cooper is an author at UNSW Sydney specializing in medicine, hiv, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	28	2.5K
2	Public Health	6	6	416
3	Health Sciences	2	2	358
4	Natural Sciences	1	1	263
5	Social Sciences	1	1	51

David A. Cooper

Publications

8.9K

Citations

H-Index

Page 1

	Year	Citations
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection Roy T. Steigbigel, David A. Cooper, Princy Kumar, New England Journal of Medicine	2008	683
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia Adriano Lazzarin, Bonaventura Clotet, David A. Cooper, New England Journal of Medicine	2003	651
A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease Sven A. Danner, Andrew Carr, John M. Leonard, New England Journal of Medicine	1995	569
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection David A. Cooper, Roy T. Steigbigel, José M. Gatell, New England Journal of Medicine	2008	505
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials Bonaventura Clotet, Nicholas Bellos, Jean‐Michel Molina, The Lancet Treatment And PreventionWeek 48Antiviral Drug DevelopmentClinical TrialsAntiviral Therapy	2007	480
Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals Martin Markowitz, Javier O Morales-Ramirez, Bach‐Yen Nguyen, JAIDS Journal of Acquired Immune Deficiency Syndromes	2006	363
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years Mark Nelson, Christine Katlama, David A. Cooper, AIDS	2007	348
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials Charles B. Hicks, Pedro Cahn, David A. Cooper, The Lancet Durable EfficacyTreatment-experienced Hiv-1-infected PatientsHiv/aids CounsellingStrategic InterventionHealth Sciences	2006	322
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials Joseph J. Eron, Benjamin Young, David A. Cooper, The Lancet Switchmrk 1Treatment And PreventionHuman RetrovirusClinical TrialsAntiviral Therapy	2010	312
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia Jun-shan Liang, Oliver Distler, David A. Cooper, Nature Medicine Protease Inhibitor-induced HyperlipidemiaBiochemistryMedicineHiv Protease InhibitorsProteomics	2001	263

Page 1